Amgen Inc (AMGN)vsEquinor ASA ADR (EQNR)
AMGN
Amgen Inc
$336.29
+2.03%
HEALTHCARE · Cap: $177.71B
EQNR
Equinor ASA ADR
$36.69
-0.60%
ENERGY · Cap: $91.44B
Smart Verdict
WallStSmart Research — data-driven comparison
Equinor ASA ADR generates 180% more annual revenue ($104.26B vs $37.22B). AMGN leads profitability with a 21.0% profit margin vs 5.3%. EQNR appears more attractively valued with a PEG of 0.93. EQNR earns a higher WallStSmart Score of 65/100 (B-).
AMGN
Buy62
out of 100
Grade: C+
EQNR
Strong Buy65
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-3.0%
Fair Value
$321.90
Current Price
$336.29
$14.39 premium
Margin of Safety
+46.5%
Fair Value
$53.41
Current Price
$36.69
$16.72 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 101 in profit
Strong operational efficiency at 33.8%
Large-cap with strong market position
Keeps 21 of every $100 in revenue as profit
Generating 1.5B in free cash flow
Strong operational efficiency at 31.5%
Large-cap with strong market position
Growing faster than its price suggests
Attractively priced relative to earnings
Earnings expanding 29.2% YoY
Generating 2.1B in free cash flow
Areas to Watch
Expensive relative to growth rate
Trading at 19.7x book value
4.4% earnings growth
5.3% margin — thin
Weak financial health signals
Revenue declined 5.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : AMGN
The strongest argument for AMGN centers on Return on Equity, Operating Margin, Market Cap. Profitability is solid with margins at 21.0% and operating margin at 33.8%.
Bull Case : EQNR
The strongest argument for EQNR centers on Operating Margin, Market Cap, PEG Ratio. PEG of 0.93 suggests the stock is reasonably priced for its growth.
Bear Case : AMGN
The primary concerns for AMGN are PEG Ratio, Price/Book, EPS Growth.
Bear Case : EQNR
The primary concerns for EQNR are Profit Margin, Piotroski F-Score, Revenue Growth.
Key Dynamics to Monitor
AMGN profiles as a mature stock while EQNR is a value play — different risk/reward profiles.
AMGN carries more volatility with a beta of 0.43 — expect wider price swings.
AMGN is growing revenue faster at 5.8% — sustainability is the question.
EQNR generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
EQNR scores higher overall (65/100 vs 62/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amgen Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.
Visit Website →Equinor ASA ADR
ENERGY · OIL & GAS INTEGRATED · USA
Equinor ASA, an energy company, is engaged in the exploration, production, transportation, refining and marketing of petroleum and petroleum products and other forms of energy, as well as other companies in Norway and internationally. The company is headquartered in Stavanger, Norway.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?